Physician profile
Sanjay P Rathi
NPI 1821007972
$540,826.45
in general payments reported to CMS, 2019-2025
58 companies · $121K in 2025
The $121K reported for 2025 was more than what 98% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $13K · 2021: $63K · 2022: $93K · 2023: $100K · 2024: $133K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $226K · Consulting Fee: $36K · Travel and Lodging: $32K · Food and Beverage: $32K · Honoraria: $27K · Education: $2,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $226,126.75 |
| Consulting Fee | $36,095.00 |
| Travel and Lodging | $31,734.18 |
| Food and Beverage | $31,616.44 |
| Honoraria | $26,528.00 |
| Education | $2,760.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $195,823.91 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $141,804.15 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $63,664.55 | 2021-2025 | Ingrezza |
| Allergan, INC. | $59,450.61 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $23,996.76 | 2022-2025 | Ongentys, Crexont, Ongentys 50mg Capsules 30 |
| Axsome Therapeutics, INC. | $10,229.37 | 2025 | Symbravo |
| Kyowa Kirin, INC. | $7,720.39 | 2019-2025 | Nourianz |
| Celgene Corporation | $7,334.25 | 2021-2025 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $7,214.46 | 2019-2024 | Zeposia |
| Genzyme Corporation | $4,450.65 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,836.22 | 2019-2025 | |
| Biogen, INC. | $1,242.92 | 2019-2024 | Tysabri, Vumerity, Tecfidera |
| Lundbeck LLC | $949.04 | 2019-2025 | Vyepti |
| Amgen INC. | $946.67 | 2019-2025 | Uplizna |
| Genentech, INC. | $892.70 | 2022-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $875.64 | 2021-2025 | |
| Sk Life Science, INC. | $859.92 | 2021-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $780.78 | 2019-2025 | Austedo Xr, Austedo Xr |
| Genentech USA, INC. | $777.23 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Janssen Pharmaceuticals, INC | $603.90 | 2020-2022 | |
| Mdd US Operations, LLC | $576.60 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Ucb, INC. | $546.07 | 2019-2025 | Zilbrysq, Rystiggo |
| Mallinckrodt Hospital Products INC. | $514.09 | 2023-2025 | Acthar |
| Tg Therapeutics, INC. | $511.86 | 2023-2025 | |
| Neurelis, INC. | $473.79 | 2020-2023 | Valtoco |
| Argenx US, INC. | $402.04 | 2022-2025 | Vyvgart |
| Horizon Therapeutics Plc | $399.47 | 2022-2023 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $392.35 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $386.74 | 2019-2025 | Dysport |
| Jazz Pharmaceuticals INC. | $369.09 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $321.25 | 2022-2024 | Amvuttra |
| Lilly USA, LLC | $274.28 | 2021-2024 | Kisunla |
| Abbott Laboratories | $263.03 | 2025 | Infinity |
| Otsuka America Pharmaceutical, INC. | $249.99 | 2023-2025 | Nuedexta, Rexulti |
| Acadia Pharmaceuticals INC | $224.48 | 2019-2025 | Nuplazid |
| Sumitomo Pharma America, INC. | $143.29 | 2023 | Aptiom |
| Merz Pharmaceuticals, LLC | $140.46 | 2021-2024 | Xeomin |
| Ani Pharmaceuticals, INC. | $140.31 | 2023 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company Ltd. | $139.01 | 2022 | |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Ponvory |
| Alexion Pharmaceuticals, INC. | $124.99 | 2023 | Ultomiris |
| Impel Pharmaceuticals INC. | $124.80 | 2022 | |
| Sunovion Pharmaceuticals INC. | $124.72 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $124.47 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $122.06 | 2023 | Relyvrio |
| Akcea Therapeutics, INC. | $119.75 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $118.93 | 2024 | Lumryz |
| Pfizer INC. | $117.82 | 2023-2024 | |
| Acorda Therapeutics, INC | $115.00 | 2019 | |
| Grifols USA, LLC | $96.01 | 2024 | Gamunex-C |
| Promius Pharma LLC | $94.45 | 2019 | |
| Medtronic, INC. | $93.64 | 2023 | Percept Pc Brainsense |
| Sanofi-Aventis U.S. LLC | $91.66 | 2023 | |
| Cycle Pharmaceuticals INC | $80.14 | 2025 | Tascenso Odt, Bafiertam |
| Supernus Pharmaceuticals, INC. | $65.85 | 2021 | |
| Adamas Pharmaceuticals, INC. | $64.01 | 2019 | |
| Strongbridge US INC. | $62.48 | 2020 | |
| Xeris Pharmaceuticals, INC. | $38.35 | 2024-2025 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Rathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.